Growing Focus on Neurological Biomarker Research
Biomarkers are disease-specific molecular indicators. In early days,the neurological disease biomarkers were not that accessible; however, the advancements in the technology have enabled the measurement of specific biomarkers for tracking the health of the brain. This helps in the early detection of a disease and less invasive diagnostics, and enables faster drug development.
Rapid developments in healthcare and drug discovery sector are leading to the introduction of new therapeutic solutions for the treatment of neurological diseases. Authorities such as World Health Organization, National Institute of Neurological Disorders and Stroke, and National Institutes of Health are taking constructive steps to encourage the research activities and find a remedy for neurological disease treatment.
Download sample PDF Brochure Here
A biomarker is an indicator of normal biological processes, pathogenic processes, or evaluating a therapeutic intervention. Thus, the discovery of biomarker is an active research area, where a few biomarkers have been sufficiently studied and validated for its use in clinical practice and clinical trials.
The National Institute of Neurological Disorders and Stroke (NINDS) biomarker program is focused on enhancing the quality and efficiency of neurotherapeutic clinical research and supports the biomarker validation. The program promotes rigorous biomarker identification and validation by providing funds for the research activities. Similarly, Parkinson’s Disease Biomarkers Program (PDBP) was initiated to support new and existing research promoting the discovery of biomarker for Parkinson's disease.
Based on product, the global neurological biomarker market is segmented into proteomics biomarker, genomics biomarker, metabolomics biomarker, imaging biomarker, and others. In 2019, the genomic biomarkers held the largest share of the market, and the market for the same is expected to grow at the fastest CAGR during the forecast period. This lucrative growth of the market for genomic biomarkers is attributed to increasing awareness among consumers regarding the benefits of genetic medicines as well as technological advancements in the field of neurological biomarkers. In addition, the shift in preference toward gene counseling and genetic analysis for diagnostic purposes is also likely to fuel the growth of the segmental market. The genetic biomarkers are significant modalities that directs toward a more personalized approach for predispositions and medical analysis.
The global neurological biomarker market, based on application,is segmented into Alzheimer's disease, Parkinson's disease, schizophrenia, Huntington's disease, spinal muscular atrophy, and others. The Alzheimer's diseasesegment held the greatest share of the market in 2019. Moreover, it is also estimated to register the highest CAGR in the marketduring 2020–2027.
Source: The Insight Partners